48results about How to "Reduced potency" patented technology

A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (¹⁰Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding ¹⁰Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

The present invention relates to an antibody comprising a GlcNAc-S(A)_x substituent, wherein S(A)_x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)_x substituent is bonded to the antibody via CI of the N-acetylglucosamine of said GlcNAc-S(A)_x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament. In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.

Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.

The invention relates to a novel poultry micro-ecological preparation and a preparation method of the novel poultry micro-ecological preparation. The preparation comprises following components in part by weight: 0.8-3.5 parts of vitamin A, 0.2-0.8 part of vitamin D, 2-8 parts of vitamin E, 0.2-1.2 parts of vitamin K, 0.1-0.9 part of vitamin B1, 0.2-0.8 part of vitamin B2, 0.1-0.7 part of vitamin B6, 0.08-0.5 part of vitamin B12, 2-5 parts of nicotinamide, 0.8-3.5 parts of calcium pantothenate, 0.02-0.4 part of folic acid, 0.2-1.2 parts of biotin, 0.02-2 parts of vitamin C, 1.3-32 parts of enterococcus faecium, 27-155 parts of bacillus subtilis, 75-210 parts of oligosaccharide, 150-400 parts of pine needle meal and 400-600 parts of bentonite. The novel poultry micro-ecological preparation can improve daily gain, feed intake, feed conversation efficiency of young poultry, reduces death and culling rate of the young poultry, and improves reproductive performance of breeding poultry, laying rate, fertilization rate of hatching eggs, hatching rate, and healthy rate of the young poultry. According to the invention, as double-layer shallow coating is performed to enterococcus faecium, the stress resistance of enterococcus faecium is improved.

Disclosed are a liquid product of botulinum toxin type A and a method for conserving the potency of botulinum toxin type A using a dextrose solution. Free of a stabilizer, such as albumin or gelatin, the liquid product of botulinum toxin type A completely excludes the possibility of cross infections such as AIDS and bovine spongiform encephalopathy. In addition, botulinum toxin type A is preserved as a liquid product in combination with a dextrose solution and can be clinically used as is, without the aid of physiological saline. Therefore, the liquid product enjoys the advantage of being convenient for use and avoiding a decrease in the potency as occurs upon dilution with physiological saline. Serving as a natural preserving and stabilizing agent, the dextrose solution allows botulinum toxin type A to be stored and distributed in the form of liquid phase over a long period of time and conserves the potency of the toxin at a constant level, which in turn guarantees constant clinical results.

A method of ameliorating the hidden node problem in wireless local area networks employing power control is disclosed. The illustrative embodiments function in a variety of ways that have a common theme: while the Data Frames are transmitted at lesser potency, at least one of the control frames—Request-to-Send, Clear-to-Send, and Acknowledgement—associated with the Data Frame are sent at a greater potency. This causes at least one of the “loud” control frames to be heard and decoded by all of the potentially contending stations. And because the control frames carry duration information for the virtual carrier sense mechanism, their reception suppresses transmissions by potentially-contending stations that cannot sense the “quiet” Data Frames.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.

The invention discloses a compound terramycin injection and a preparation method thereof. The compound terramycin injection comprises, by weight, 20 parts of terramycin, 2 parts of flunixin meglumine, 30-40 parts of propylene glycol, 10-15 parts of dimethyl formamide, 3 parts of polyvinylpyrrolidone, 6-7 parts of magnesium oxide, 0.5 parts of an anti-oxidant, 6.1-6.5 parts of ethanolamine and 28 parts of injection water. The compound terramycin injection can be used for treating therapy-sensitive infectious diseases caused by gram-positive bacteria and gram-negative bacteria, rickettsia and mycoplasma and has good treatment effects. The compound terramycin injection has good stability, does not discolor after being heated or stored for a long time, does not product precipitates, solves the problem that under the acid or alkaline conditions, the existing terramycin injection discolors or precipitates after being heated or stored for a long time so that titer is reduced, and can slowly release drug active components in the human body so that long-acting effects are obtained.

An organic herbicide is disclosed and comprises oxidized natural oils such as clove oil, and cinnamon oil. A natural surfactant is disclosed comprising 30-50% by weight casein, 50-70% by weight whole egg powder and 0-5% by weight Konjac glucomannan.

An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.